Regeneron Pharmaceuticals, Inc. - Common Stock

Geoff Meacham: We were very bullish on the biotech group in 2010 and 2011. Fundamentals are still very good, but I would say we're more cautious on the performance of the group for all of 2012.

Quarterly earnings reports can have big effects on a biotech stock price, especially if a company has just launched a newly approved drug.

by Elizabeth Harrow 2/6/2012 11:12 AM Analysts are weighing in today on global courier FedEx Corporation (FDX - 94.96), agricultural equipment giant Deere & Company (DE - 87.23), casino operator MGM Resorts International (MGM - 14.11), biotech stock ...

(RTTNews) - The biotechnology sector, though a risky investment arena, offers a tremendous potential for huge gains. Binary events like clinical trial results and FDA decisions are typical in biotechnology companies, and can cause significant swings in ...

National Bank of Greece (ADR) (NYSE:NBG) is the 1st best-performing stock year-to-date in this segment of the market. It is up 88.9% year-to-date, and it is down 63.9% for the last 52 weeks.